Amp Volatility Score
Catalyst Info & Data Links
TITLE: mRNA-1273 COVID-19 Drug
ClinicalTrial.gov (NCT04283461): Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
WHAT IS THE NEXT CATALYST EVENT?
July 2020 Phase 3 trial begins
TBD: Additional Phase 2 data
WHEN WILL THE EVENT (OR DID THE EVENT) OCCUR?
05-2020: Business Updates and First Quarter 2020 Financial Results (slides 15-19)
2019: mRNA vaccines against H10N8 and H7N9 influenza viruses of pandemic potential are immunogenic and well tolerated in healthy adults in phase 1 randomized clinical trials. Vaccine, 37(25), 3326-3334.
2020: An mRNA Vaccine against SARS-CoV-2 — Preliminary Report. New England Journal of Medicine
MECHANISM OF ACTION / RATIONALE
mRNA-1273 is an mRNA vaccine against SARS-CoV-2 encoding for a prefusion stabilized form of the Spike (S) protein, which was selected by Moderna in collaboration with investigators from Vaccine Research Center (VRC) at the National Institute of Allergy and Infectious Diseases (NIAID), a part of the NIH.
Updated by HC
MRNA, mRNA-1273, COVID-19
Prior Data (click to view full image)
Trial Design / Revenue (click to view full image)
See What The Community Is Saying - Click To See Full Post